Duvelisib not checked

SecuraBio · IPI-145 · PI3K Inhibitor

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 3 trial completes
Trials
2 active
24 in total · 1 in the EU
Targets
 

What this is

How it works
Blocks PI3K, an enzyme that passes growth signals inside cells. Mostly used against cancer.-lisib: PI3K inhibitors WHO name stem
Tested for
Lymphoma, Mycosis Fungoides, Cutaneous T-cell Lymphoma
Main trialPhase 3
“The study will evaluate the progression-free survival benefit of duvelisib monotherapy as compared to investigator's choice of gemcitabine or bendamustine in participants with relapsed/refractory nodal T cell lymphoma with TFH phenotype.”In the company’s words, NCT06522737 on ClinicalTrials.gov
Other names
IPI-145 · Copiktra · PI3K Inhibitor · SBI-0145 · VS-0145

Other drugs for Lymphoma

All 308 drugs for Lymphoma

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials24

TrialPhaseCompletesWhat it tests
Phase 3Recruiting Feb 2028 A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype
Phase 1Not yet recruiting Oct 2028 A Study of Topical Duvelisib in Participants With Early-stage Mycosis Fungoides
Phase 3Withdrawn Nov 2016 A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)
Phase 3Terminated Dec 2016 Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma
Phase 3Completed 19 May 2017 A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)
Phase 3Completed 12 Jun 2020 A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07
Phase 2Completed Aug 2014 A Phase 2a, Efficacy and Safety Study of Duvelisib in Mild Asthmatic Subjects
Phase 2Completed Dec 2014 A Double-Blind Study Evaluating Duvelisib in Subjects With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone
Phase 2Withdrawn Nov 2016 Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)
Phase 2Completed 4 May 2020 A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145)
Phase 2Withdrawn Jun 2020 Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma
Phase 2Completed 18 Nov 2020 A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma
Phase 2Completed 24 Jul 2023 A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin Lymphoma
Phase 2Completed 22 Dec 2023 A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Phase 1/2Terminated 17 Jan 2017 A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)
Phase 1/2Terminated 10 Dec 2020 A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer
Phase 1Completed Feb 2012 IPI-145 Single Ascending, Multiple Ascending, Food Effect and Drug-Drug-Interaction Study
Phase 1Completed Apr 2013 IPI-145 ADME and Absolute Bioavailability Study
Phase 1Completed Sep 2013 Phase 1 Study in Healthy Subjects to Evaluate the Effect of IPI-145 on the Pharmacokinetics of Midazolam
Phase 1Completed Nov 2013 Phase 1 Study in Healthy Subjects to Evaluate the Effect of Rifampin on the Pharmacokinetics of IPI-145
Phase 1Completed Jul 2014 Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects
Phase 1Completed Aug 2015 Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145
Phase 1Terminated Nov 2016 Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)
Phase 1Terminated Dec 2016 A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Duvelisib

Following is part of Solo: you see every change to Duvelisib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in